News
College of Human Medicine recruits leading cancer researchers Jeff and Jenny Klomp
On a sunny morning this past June, scientists around the world woke up to news that could fundamentally change the game in cancer research and care. And two of the people behind that breakthrough are now working at Michigan State University.
Jenny Klomp, PhD, and Jeff Klomp, PhD, were recently recruited to the College of Human Medicine as assistant professors in the Department of Medicine. They began establishing their labs at the Grand Rapids Research Center in August.
Bachmann’s pioneering DFMO research leads to FDA-approved lifesaving cancer drug
The U.S. Food and Drug Administration has approved a drug to treat neuroblastoma, an often-fatal pediatric cancer, based on pioneering research by College of Human Medicine professor André Bachmann.
The FDA approved a tablet form of a drug called difluoromethylornithine, or DFMO (synonym eflornithine), developed in 1978 and later used to treat West African sleeping sickness. The agency’s approval will allow doctors to use oral DFMO to reduce the rate of relapses in patients who have previously undergone standard therapy for neuroblastoma.
MSU researchers find early, promising glioblastoma treatment
A team of Michigan State University scientists has unveiled a potential game-changer in the fight against glioblastoma, the most common and currently incurable form of brain cancer.
Their weapon of choice? A drug-like compound named Ogremorphin, or OGM. In laboratory experiments, OGM showed a remarkable ability to kill glioblastoma cells while leaving normal cells unharmed.